Relmada Therapeutics (RLMD) Equity Ratio (2012 - 2026)

Relmada Therapeutics (RLMD) has 15 years of Equity Ratio data on file, last reported at 0.93 in Q1 2026.

• Equity Ratio for Q1 2026 came in at 0.93, up 14.63% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.93 (up 14.63% YoY), and the FY2025 annual result was 0.92, up 18.71% from the prior year.
• Equity Ratio advanced to 0.93 in Q1 2026 per RLMD's latest filing, from 0.92 in the prior quarter.
• Over five years, Equity Ratio peaked at 0.93 in Q1 2022 and troughed at 0.64 in Q3 2025.
• A 5-year average of 0.86 and a median of 0.89 in 2022 frame the typical range for Equity Ratio.
• On a YoY basis, Equity Ratio climbed as much as 18.71% in 2025 and fell as far as 25.55% in 2025.
• A 5-year view of Equity Ratio shows it stood at 0.92 in 2022, then decreased by 4.73% to 0.87 in 2023, then fell by 11.39% to 0.78 in 2024, then increased by 18.71% to 0.92 in 2025, then increased by 0.98% to 0.93 in 2026.
• Business Quant data shows RLMD's Equity Ratio at 0.93 in Q1 2026, 0.92 in Q4 2025, and 0.64 in Q3 2025.